Detailed sponsorship packages and benefits are outlined in the MTERMS 2026 Sponsorship Prospectus (PDF brochure & form).
View packages, benefits, and the sponsorship form.
Download Sponsorship ProspectusFor sponsorship enquiries, partnership discussions, or customized packages:
MTERMS 2026 Sponsorship Committee
Assoc. Prof. Dr. Yogeswaran Lokanathan
Lyoges@hctm.ukm.edu.my
The Malaysian Tissue Engineering and Regenerative Medicine Scientific Meeting 2026 (MTERMS 2026) is a premier biennial scientific conference organized by the Tissue Engineering and Regenerative Medicine Society of Malaysia (TESMA). The conference serves as a dynamic platform for advancing research, innovation, and collaboration in tissue engineering, regenerative medicine, cell and gene therapy, biomaterials, and related translational sciences.
MTERMS 2026 is expected to attract local and international scientists, clinicians, academicians, industry leaders, policy makers, and postgraduate students, providing sponsors with a unique opportunity to engage with a highly specialized and influential audience.
By partnering with MTERMS 2026, your organization will gain:
Sponsorship opportunities are ideal for:
A range of customizable sponsorship and exhibition packages will be available, including but not limited to:
Detailed sponsorship packages and benefits are outlined in the MTERMS 2026 Sponsorship Prospectus .
We warmly invite your esteemed organization to become a Sponsor or Partner of MTERMS 2026. Your support will contribute significantly to the success of the conference while reinforcing your organization’s commitment to advancing science, healthcare, and innovation.
Confirmed sponsors will be announced here. Company logos will link directly to the sponsor’s official website.
Biolive Malaysia is a biotechnology company committed to advancing preventive healthcare, regenerative medicine, and healthy aging through science-driven innovations. As part of a global biotechnology network, Biolive specializes in the development, manufacturing, and distribution of high-quality biopharmaceuticals, nutraceuticals, and medical devices designed to enhance health and improve quality of life.
Our portfolio focuses on supporting immune function, cellular regeneration, and overall wellness by integrating the latest advancements in biotechnology with evidence-based research.
Beyond product innovation, Biolive actively collaborates with universities, healthcare professionals, clinicians, and research institutions to promote scientific exchange and accelerate the translation of research into clinical and community applications.
Through educational seminars, strategic partnerships, and research initiatives, we strive to bridge the gap between laboratory discoveries and real-world healthcare solutions.
Guided by our commitment to innovation, quality, and scientific excellence, Biolive continues to contribute towards a healthier future by delivering accessible, reliable, and impactful biotechnology solutions for communities worldwide.
Histocenter (M) Sdn. Bhd. is a 100% Malaysian-owned company established in 1987, providing technology solutions to the scientific, medical, diagnostic, research, and industrial communities. Building upon its core expertise in histology and pathology solutions, the company has expanded its portfolio to encompass comprehensive microscopy systems, digital imaging hardware and software, analytical instruments, laboratory apparatus, and related scientific solutions.
Serving customers across both the public and private sectors, Histocenter supports hospitals and medical centres, universities, research institutions, independent laboratories, veterinary services, government agencies, educational institutions, and industrial organisations throughout Malaysia. Beyond supplying scientific technologies, the company focuses on understanding customer requirements, developing appropriate solutions, and providing ongoing technical and after-sales support to help laboratories and institutions achieve reliable and effective outcomes.
AuctuCel Malaysia, a subsidiary of Singapore’s A*STAR spin-off AuctuCel, is an advanced bioprocessing company transforming cell culture media development. Powered by proprietary computational modeling and metabolic flux prediction platforms, we engineer customized media formulations tailored for biomanufacturing, regenerative medicine, and cell and gene therapies (CGT).
Alongside our bespoke optimization services, AuctuCel delivers a comprehensive portfolio of ready-to-use, fully chemically defined, serum-free, and xeno-free media—including MSC, iPSC, immune cell, CHO, and HEK293 formulations. Available in both Research-Grade and cGMP-compliant formats, our products eliminate biological batch variability and match global bioprocessing benchmarks to accelerate clinical translation and scale-up.
Want to be featured here? Email: Lyoges@hctm.ukm.edu.my